NI201100017A - Composiciones y métodos de uso para anticuerpos terapéuticos. - Google Patents
Composiciones y métodos de uso para anticuerpos terapéuticos.Info
- Publication number
- NI201100017A NI201100017A NI201100017A NI201100017A NI201100017A NI 201100017 A NI201100017 A NI 201100017A NI 201100017 A NI201100017 A NI 201100017A NI 201100017 A NI201100017 A NI 201100017A NI 201100017 A NI201100017 A NI 201100017A
- Authority
- NI
- Nicaragua
- Prior art keywords
- compositions
- methods
- antibodies
- therapeutic antibodies
- baffr
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
La presente invención se refiere a anticuerpos que se enlazan específicamente al receptor de BAFF (BAFFR). La invención se refiere de una manera más específica, a anticuerpos específicos que son antagonistas del BAFFR, con actividad consumidora de células-B in vivo, y a composiciones y métodos de uso para estos anticuerpos con el fin de tratar los trastornos patológicos que puedan ser tratados mediante la aniquilación o el consumo de las células-B, tales como lupus eritematoso sistémico o artritis reumatoide, u otras enfermedades autoinmunes o linfomas, leucemias, y mielomas.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08160671 | 2008-07-17 | ||
| EP09160326 | 2009-05-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NI201100017A true NI201100017A (es) | 2012-08-17 |
Family
ID=41073830
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NI201100017A NI201100017A (es) | 2008-07-17 | 2011-01-14 | Composiciones y métodos de uso para anticuerpos terapéuticos. |
Country Status (41)
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2222846B1 (en) * | 2007-08-10 | 2017-05-03 | Protelix, Inc. | Universal fibronectin type iii binding-domain libraries |
| US8470966B2 (en) | 2007-08-10 | 2013-06-25 | Protelica, Inc. | Universal fibronectin type III binding-domain libraries |
| US8680019B2 (en) * | 2007-08-10 | 2014-03-25 | Protelica, Inc. | Universal fibronectin Type III binding-domain libraries |
| WO2012076670A2 (en) | 2010-12-10 | 2012-06-14 | Novartis Ag | Antibody formulation |
| JP2012153788A (ja) * | 2011-01-25 | 2012-08-16 | Nitto Denko Corp | 光学用粘着シート |
| US9216219B2 (en) | 2012-06-12 | 2015-12-22 | Novartis Ag | Anti-BAFFR antibody formulation |
| US10435474B2 (en) | 2013-12-24 | 2019-10-08 | Ossianix, Inc. | Baff selective binding compounds and related methods |
| CA2934965A1 (en) | 2014-01-31 | 2016-03-17 | Boehringer Ingelheim International Gmbh | Novel anti-baff antibodies |
| MA41044A (fr) | 2014-10-08 | 2017-08-15 | Novartis Ag | Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer |
| MA40035A (fr) | 2014-10-14 | 2016-04-21 | Dana Farber Cancer Inst Inc | Molécules d'anticorps de pd-l1 et leurs utilisations |
| PT3317301T (pt) | 2015-07-29 | 2021-07-09 | Novartis Ag | Terapias de associação compreendendo moléculas de anticorpo contra lag-3 |
| EP3878465A1 (en) | 2015-07-29 | 2021-09-15 | Novartis AG | Combination therapies comprising antibody molecules to tim-3 |
| WO2017106656A1 (en) | 2015-12-17 | 2017-06-22 | Novartis Ag | Antibody molecules to pd-1 and uses thereof |
| BR112018015272A2 (pt) | 2016-02-10 | 2018-12-18 | Novartis Ag | uso de inibidores da atividade ou função de pi3k para o tratamento de síndrome de sjögren primária |
| US11136405B2 (en) * | 2016-06-06 | 2021-10-05 | Board Of Regents, The Unviersity Of Texas System | BAFF-R antibodies and uses thereof |
| US11197928B2 (en) | 2017-01-13 | 2021-12-14 | Board Of Regents, The University Of Texas System | Sustained production of high affinity antigen specific antibody by high dose BAFF receptor-targeting mAb-siRNA conjugate |
| WO2018217918A2 (en) * | 2017-05-24 | 2018-11-29 | Als Therapy Development Institute | Therapeutic anti-cd40 ligand antibodies |
| CN110891971B (zh) | 2017-06-20 | 2024-01-12 | 特尼奥生物股份有限公司 | 仅有重链的抗bcma抗体 |
| CN112351997B (zh) * | 2018-07-20 | 2023-05-26 | 坦尼奥第二公司 | 与cd19结合的重链抗体 |
| WO2020202839A1 (ja) * | 2019-03-29 | 2020-10-08 | 中外製薬株式会社 | 抗ｉｌ－６受容体抗体を含有するｂｂｂ機能低下の抑制剤 |
| US20220356261A1 (en) | 2019-11-06 | 2022-11-10 | Novartis Ag | Treatment for sjögren's syndrome |
| CN112813099A (zh) * | 2019-11-15 | 2021-05-18 | 上海细胞治疗集团有限公司 | 一种在活化的t细胞中具有高活性的启动子 |
| CN116096414A (zh) | 2020-08-04 | 2023-05-09 | 诺华股份有限公司 | Cll的治疗 |
| IL300086A (en) | 2020-08-04 | 2023-03-01 | Novartis Ag | Treatment of B-cell malignancies |
| CN114149504B (zh) * | 2020-09-07 | 2024-01-12 | 白先宏 | Baff-r结合分子及其应用 |
| CN116390933A (zh) | 2020-11-06 | 2023-07-04 | 诺华股份有限公司 | 治疗b细胞恶性肿瘤的抗cd19剂和b细胞靶向剂组合疗法 |
| CN115073598B (zh) * | 2021-03-15 | 2024-02-20 | 盛禾(中国)生物制药有限公司 | 一种抗baffr抗体及其应用 |
| KR20240004761A (ko) | 2021-05-04 | 2024-01-11 | 노파르티스 아게 | 항-baffr 항체를 사용한 전신 홍반성 루푸스의 치료 |
| CA3216063A1 (en) | 2021-05-04 | 2022-11-10 | Novartis Ag | Treatment for lupus nephritis using anti-baffr antibodies |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20090016772A (ko) * | 1999-08-17 | 2009-02-17 | 바이오겐 아이덱 엠에이 인코포레이티드 | Ｂａｆｆ 수용체(ｂｃｍａ), 면역조절제 |
| UA83458C2 (uk) | 2000-09-18 | 2008-07-25 | Байоджен Айдек Ма Інк. | Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf) |
| CA2595112A1 (en) * | 2004-12-31 | 2006-07-13 | Genentech, Inc. | Polypeptides that bind br3 and uses thereof |
| WO2008008482A2 (en) * | 2006-07-13 | 2008-01-17 | Genentech, Inc. | Altered br3-binding polypeptides |
-
2009
- 2009-07-15 DK DK09797499.2T patent/DK2315780T3/en active
- 2009-07-15 NZ NZ590057A patent/NZ590057A/xx unknown
- 2009-07-15 PE PE2011000038A patent/PE20110563A1/es active IP Right Grant
- 2009-07-15 KR KR1020117001052A patent/KR101314369B1/ko active IP Right Grant
- 2009-07-15 CA CA2730063A patent/CA2730063C/en active Active
- 2009-07-15 PL PL09797499T patent/PL2315780T3/pl unknown
- 2009-07-15 BR BRPI0915928A patent/BRPI0915928B8/pt active IP Right Grant
- 2009-07-15 SG SG2013062567A patent/SG193805A1/en unknown
- 2009-07-15 SI SI200931293T patent/SI2315780T1/sl unknown
- 2009-07-15 GE GEAP200912063A patent/GEP20146129B/en unknown
- 2009-07-15 EP EP09797499.2A patent/EP2315780B8/en active Active
- 2009-07-15 MY MYPI2010005960A patent/MY158980A/en unknown
- 2009-07-15 US US12/503,175 patent/US8106163B2/en active Active
- 2009-07-15 JP JP2011517915A patent/JP5767109B2/ja active Active
- 2009-07-15 PT PT97974992T patent/PT2315780E/pt unknown
- 2009-07-15 MX MX2011000616A patent/MX2011000616A/es active IP Right Grant
- 2009-07-15 CN CN200980127408.2A patent/CN102119174B/zh active Active
- 2009-07-15 ES ES09797499.2T patent/ES2547270T3/es active Active
- 2009-07-15 AU AU2009272771A patent/AU2009272771B2/en active Active
- 2009-07-15 KR KR1020137019574A patent/KR101545795B1/ko active IP Right Grant
- 2009-07-15 HU HUE09797499A patent/HUE025778T2/en unknown
- 2009-07-15 UY UY0001031987A patent/UY31987A/es active IP Right Grant
- 2009-07-15 EA EA201100191A patent/EA024492B1/ru not_active IP Right Cessation
- 2009-07-15 WO PCT/EP2009/059030 patent/WO2010007082A1/en active Application Filing
- 2009-07-15 AR ARP090102678A patent/AR072749A1/es active IP Right Grant
- 2009-07-15 RS RS20150667A patent/RS54299B1/en unknown
- 2009-07-16 JO JOP/2009/0267A patent/JO3149B1/ar active
- 2009-07-16 TW TW098124126A patent/TWI508742B/zh active
-
2010
- 2010-12-13 ZA ZA2010/08952A patent/ZA201008952B/en unknown
- 2010-12-21 CR CR11863A patent/CR11863A/es unknown
-
2011
- 2011-01-06 IL IL210485A patent/IL210485A/en active IP Right Grant
- 2011-01-14 NI NI201100017A patent/NI201100017A/es unknown
- 2011-01-14 MA MA33525A patent/MA32481B1/fr unknown
- 2011-01-14 CL CL2011000086A patent/CL2011000086A1/es unknown
- 2011-01-14 DO DO2011000016A patent/DOP2011000016A/es unknown
- 2011-01-17 EC EC2011010761A patent/ECSP11010761A/es unknown
- 2011-01-17 SV SV2011003807A patent/SV2011003807A/es unknown
- 2011-01-17 CU CUP2011000013A patent/CU23878B1/es active IP Right Grant
- 2011-02-17 SM SM201100010T patent/SMP201100010B/it unknown
- 2011-05-17 HK HK11104814.3A patent/HK1150839A1/xx unknown
- 2011-12-15 US US13/326,514 patent/US9340620B2/en active Active
- 2011-12-15 US US13/326,569 patent/US9382326B2/en active Active
-
2015
- 2015-04-10 JP JP2015081099A patent/JP6077587B2/ja active Active
- 2015-10-19 CY CY20151100934T patent/CY1116800T1/el unknown
- 2015-11-13 HR HRP20151227TT patent/HRP20151227T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NI201100017A (es) | Composiciones y métodos de uso para anticuerpos terapéuticos. | |
| CO6771417A2 (es) | Antagonistas del receptor de ácido lisofosfatidico y su uso en el tratamiento de fibrosis | |
| CL2018000353A1 (es) | Agentes inductores de la apoptosis para tratar el cáncer y enfermedades inmunes y autoinmunes | |
| CO6480918A2 (es) | Antagonistas policíclicos de receptores de ácido lisofosfatídico. | |
| ECSP11010932A (es) | Compuestos de azaindazol como antagonistas del receptor de ccr1 | |
| CL2016000408A1 (es) | Composiciones farmaceuticas que contienen diastereomeros macrolidos, metodos para su sintesis y usos terapeuticos. | |
| EA201691070A1 (ru) | Новые трициклические соединения в качестве противораковых средств | |
| UY32926A (es) | Compuestos como antagonistas de los receptores de ácido lisofosfatídico | |
| CR20120273A (es) | OCTAHIDROPIRROLO[3,4-c]PIRROLOS DISUSTITUIDOS COMO MODULADORES DEL RECEPTOR DE OREXINA | |
| EA201270720A1 (ru) | Модуляторы рецептора андрогенов и их применение | |
| EA201290940A1 (ru) | Новые соединения как селективные антагонисты рецептора nk3, фармацевтическая композиция и методы их использования при нарушениях, опосредованных nk3 рецепторами | |
| CL2008001099A1 (es) | Compuestos derivados de indazol; y su uso para tratar enfermedades mediadas por los receptores s1p1, tales como esclerosis multiple, enfermedad autoinmune, trastornos inflamatorios, diabetes, entre otras. | |
| AR054539A1 (es) | Nuevos anticuerpos anti- madcam | |
| EA201791592A1 (ru) | Кристаллические формы модулятора андрогенных рецепторов | |
| EA201890333A1 (ru) | Противовирусные соединения | |
| EA201591059A1 (ru) | МОДУЛЯТОРЫ СИРОТСКИХ ГАММА-РЕЦЕПТОРОВ РЕТИНОИДОВ (RORγ) ДЛЯ ПРИМЕНЕНИЯ ПРИ ЛЕЧЕНИИ АУТОИММУННЫХ И ВОСПАЛИТЕЛЬНЫХ ЗАБОЛЕВАНИЙ | |
| UY32923A (es) | Compuestos policíclicos como antagonistas del receptor de ácido lisofosfatídico | |
| UY32937A (es) | Compuestos y composiciones como moduladores de la actividad de gpr119 | |
| CL2015002202A1 (es) | Benzamidas sustituidas con actividad hacia receptores ep4. | |
| ECSP088807A (es) | Tetrahidro-pirimidoazepinas como moduladores del potencial transitorio de receptor vaillinoide 1 (trpv1) | |
| EA201891376A1 (ru) | Бензотиофеновые селективные блокаторы эстрогеновых рецепторов | |
| EA201690880A1 (ru) | Тетрациклические ингибиторы аутотаксина | |
| EA201101572A1 (ru) | Композиции и способы применения терапевтических антител, специфичных в отношении субъединицы бета1 рецептора il-12 | |
| UY33651A (es) | Anticuerpos anti-il12rbeta1 y su uso para tratar los trastornos autoinmunes e inflamatorios | |
| EA201591717A1 (ru) | Твердые формы гидрохлорида вемурафениба |